VANCOUVER, Washington, Feb. 21, 2020 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple...
Santa Ana, CA — (SBWIRE) — 02/20/2020 — Arthritis is one of the most leading causes of pain and disability worldwide. There are more than 100 different types of arthritis and related diseases. However, the most common types of arthritis are...
– Balstilimab and zalifrelimab combination yield >20% response rates – Balstilimab and zalifrelimab combination has best-in-class potential for the treatment of second-line cervical cancer – On track to submit 2 BLAs for these agents in 2020...
The novel peptide nerinetide, without prior administration of alteplase, improved functional outcome, reduced mortality and reduced infarct volume among acute ischemic stroke patients Data presented at the plenary session of the International Stroke Conference 2020...
BOULDER, Colo., Feb. 20, 2020 (GLOBE NEWSWIRE) — Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin...
GAINESVILLE, Fla.–(BUSINESS WIRE)–Cyclo Therapeutics, Inc. (OTCQB: CTDH), a clinical-stage biotechnology company that develops cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and Alzheimer’s Disease, today announced that it has...
Email
Text